An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1553-1564

  Hirano, Jinichi ^a,b   Watanabe, Koichiro ^c   Suzuki, Takefumi ^a,d   Uchida, Hiroyuki ^a   Den, Ryosuke ^e   Kishimoto, Taishiro ^a   Nagasawa, Takashi ^e   Tomita, Yusuke ^d   Hara, Koichiro ^f   Ochi, Hiromi ^g   Kobayashi, Yoshimi ^a   Ishii, Mutsuko ^a   Fujita, Akane ^a   Kanai, Yoshihiko ^a   Goto, Megumi ^a   Hayashi, Hiromi ^a   Inamura, Kanako ^a   Ooshima, Fumiko ^a   Sumida, Mariko ^a   Ozawa, Tomoko ^a   Sekigawa, Kayoko ^a   Nagaoka, Maki ^a   Yoshimura, Kae ^a   Konishi, Mika ^a   Inagaki, Ataru ^a   Saito, Takuya ^h   Motohashi, Nobutaka ⁱ   Mimura, Masaru ^a   Okubo, Yoshiro ^h   Kato, Motoichiro ^a   more..

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ohizumi Hospital   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Inokashira Hospital   (Japan)

^e Komagino Hospital   (Japan)

^f Asai Hospital   (Japan)

^g Kurumegaoka Hospital   (Japan)

^h NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Algorithm; Measurement based treatment; Open label clinical trial; Schizophrenia; Treatment as usual

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; BLONANSERIN; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM CARBONATE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AGED; ALGORITHM; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DSM-IV; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; PSYCHIATRIST; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 84885942474     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S46108     Document Type: Article

References (36)

1. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16-B39.
2. Miller AL, Crismon ML, Rush AJ, et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull. 2004;30(3):627-647.
3. Janssen B, Ludwig S, Eustermann H, et al. Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation-results of a multicenter-study within the German research network on schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2010;260(1):51-57.
4. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61(7):669-680.
5. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):361-369.
6. Suzuki T, Uchida H, Tanaka KF, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic Int Clin Psychopharmacol. 2003;18(6):323-329.
7. Hasan A, Falkai P, Wobrock T, et al; for World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, VA: American Psychiatric Association; 1994.
9. Haro JM, Kamath SA, Ochoa S, et al; for SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16-23.
10. Inagaki A, Inada T. [Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidone long-acting injection]. Japanese Journal of Clinical Psychopharmacology. 2010;13:1349-1353. Japanese.
11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
12. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2-3):227-238.
13. Suzuki T, Uchida H, Nomura K, et al. Novel rating scales for schizophrenia-Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res. 2008;106(2-3):328-336.
14. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: QualityMetric, Incorporated, 2000.
15. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79-88.
16. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183.
17. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751-1762.
18. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bull. 2004;30(2):193-217.
19. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68 Suppl 1:12-19.
20. Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?-A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology. 2007;195(2):285-295.
21. Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry. 2006;67(10):1577-1582.
22. Lieberman JA, Stroup TS, McEvoy JP, et al; for Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005;353(12):1209-1223.
23. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS). Arch Gen Psychiatry. 2006;63(10):1079-1087.
24. National Institute for Health and Care Excellence. Nice clinical guidelines Schizophrenia (update) (CG82). Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). NICE 2009. Available from: http://publications.nice.org.uk/schizophrenia-cg82. Accessed 01 Jan 2013.
25. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. Cochrane Database Syst Rev. 2003;(3):CD003834.
26. Suzuki T, Uchida H, Takeuchi H, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009;24(8):628-638.
27. Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs. 2010;24(1):9-20.
28. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1-2):1-6.
29. Fleischhacker WW, Keet IP, Kahn RS; for EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78(2-3):147-156.
30. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439-1444.
31. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
32. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
33. Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55(10):677-684.
34. Uchida H, Mamo DC, Pollock BG, et al. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit. 2012;34(2):182-187.
35. Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull. 2011;44(1):18-31.
36. Suzuki T, Remington G, Arenovich T, et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry. 2011;199(4):275-280.